Arcera and Innogen seal global licensing deal to expand access to next-gen diabetes and obesity drug
By: IPP Bureau
Last updated : November 22, 2026 8:44 am
Innogen will receive an upfront payment, alongside potential milestone payments and tiered royalties on net sales in the licensed territories
Abu Dhabi-based Arcera Life Sciences has struck an exclusive licensing and commercialization deal with Chinese biopharmaceutical company Innogen Pharmaceuticals to expand the international reach of Efsubaglutide Alfa, a long-acting GLP-1 therapy targeting type 2 diabetes and obesity.
The agreement gives Arcera responsibility for regulatory affairs, market access and commercialization of the drug across selected markets in Africa, Eastern Europe, Latin America and the Middle East, including the UAE.
The partnership marks a major push by Arcera into the rapidly expanding cardiometabolic treatment market, combining Innogen’s drug-development expertise with Arcera’s established international regulatory and commercial network.
Under the terms of the deal, Innogen will receive an upfront payment, alongside potential milestone payments and tiered royalties on net sales in the licensed territories. Financial details were not disclosed.
The deal comes as diabetes and obesity continue to place mounting pressure on healthcare systems worldwide. An estimated 589 million adults are living with diabetes globally, a figure projected to climb to 853 million by 2050, according to the International Diabetes Federation.
GLP-1 receptor agonists have emerged as an increasingly important class of medicines for managing type 2 diabetes and obesity. The World Health Organization added GLP-1 therapies to its Model List of Essential Medicines in 2025 and issued global guidance on their use in obesity treatment.
Efsubaglutide Alfa is a long-acting fusion protein combining a human GLP-1 analogue with an IgG Fc fragment. Studies have reported a half-life of up to 280 hours.
Clinical data showed reductions in HbA1c, a key measure of long-term blood glucose levels, of approximately 2.2 percentage points after 24 weeks of treatment.
In studies involving Chinese adults with overweight or obesity, treatment over 18 weeks delivered average weight reductions of 10.6% with once-weekly dosing and 9.7% with dosing every two weeks.
The studies also reported improvements in body composition, with the muscle-to-fat ratio increasing by up to 45.3% from baseline among participants receiving weekly doses. Researchers reported that weight loss was driven predominantly by reductions in fat mass, with relative preservation of muscle.
Liver fat content also fell by up to 51.8% with weekly dosing.
The treatment was reported to be well tolerated, with a low incidence of gastrointestinal adverse events relative to other GLP-1 receptor agonists in cross-trial comparisons. No participants discontinued treatment because of adverse events during the 18-week study period.
Innogen has also completed a Phase II clinical trial in Australia evaluating once-monthly dosing in adults with overweight or obesity, generating additional evidence to support the drug's future international development and registration.
For Arcera, the agreement represents a strategic move to establish cardiometabolic disease as a central pillar of its international business, while strengthening its position as a commercialization partner for innovative pharmaceutical companies.
Isabel Afonso, Chief Executive Officer of Arcera Life Sciences, said: “Cardiometabolic diseases remain among the most pressing healthcare challenges in the markets we serve. Our agreement with Innogen accelerates the bridge we are building between China and our international markets to bring innovative medicines to more patients and strengthen our cardiometabolic portfolio. By combining our partners’ scientific capabilities with Arcera’s regulatory expertise, market access and overall commercial reach, we aim to turn innovation into meaningful impact for people living with chronic disease.”
For Innogen, the partnership provides a route to expand beyond its established Chinese market and accelerate the global development of its proprietary drug.
Qinghua Wang, Founder, Chairman and Chief Executive Officer of Innogen Pharmaceuticals, said: “We are delighted to establish this collaboration with Arcera, which represents an important step in Innogen’s international expansion. We believe that combining world-class science with entrepreneurial innovation is key to improving patient care. Innogen’s mission is to provide best-in-class and first-in-class therapies for people living with diabetes, obesity and other metabolic diseases worldwide.
"Our collaboration with Arcera is an important step toward this vision. By combining Innogen’s scientific innovation with Arcera’s strengths in international regulatory affairs and commercialization, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world.”
The agreement remains subject to customary regulatory and operational requirements in the relevant markets. Commercialization will begin once the necessary local regulatory approvals have been secured.